These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 1472260)
1. Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin. Danesi R; Bernardini N; Agen C; Costa M; Zaccaro L; Pieracci D; Malvaldi G; Del Tacca M Cancer Chemother Pharmacol; 1992; 29(4):261-5. PubMed ID: 1472260 [TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity and cytotoxicity of the anthracycline analog 4'-deoxy-4'-iodo-doxorubicin. Danesi R; Bernardini N; Agen C; Costa M; Macchiarini P; Della Torre P; Del Tacca M Toxicology; 1991; 70(2):243-53. PubMed ID: 1763418 [TBL] [Abstract][Full Text] [Related]
3. Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin. Pinna A; Agen C; Di Paolo A; Innocenti F; Nardini D; Danesi R; Del Tacca M J Environ Pathol Toxicol Oncol; 1994; 13(1):25-31. PubMed ID: 7823290 [TBL] [Abstract][Full Text] [Related]
4. Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol. Danesi R; Marchetti A; Bernardini N; La Rocca RV; Bevilacqua G; Del Tacca M Cancer Chemother Pharmacol; 1990; 26(6):403-8. PubMed ID: 2171795 [TBL] [Abstract][Full Text] [Related]
5. 3'-Deamino-3'-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. Danesi R; Agen C; Grandi M; Nardini V; Bevilacqua G; Del Tacca M Eur J Cancer; 1993; 29A(11):1560-5. PubMed ID: 8217363 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin. Villani F; Galimberti M; Lanza E; Rozza A; Favalli L; Poggi P Invest New Drugs; 1988 Sep; 6(3):173-8. PubMed ID: 3192383 [TBL] [Abstract][Full Text] [Related]
7. Characterization of the toxicity of distamycin derivatives on cancer cell lines and rat heart. Agen C; Sironi AM; Danesi R; Costa M; Bernardini N; Paparelli A; Della Torre P; Del Tacca M Toxicology; 1992 Nov; 75(3):209-19. PubMed ID: 1455430 [TBL] [Abstract][Full Text] [Related]
8. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Agen C; Bernardini N; Danesi R; Della Torre P; Costa M; Del Tacca M Cancer Chemother Pharmacol; 1992; 30(2):95-9. PubMed ID: 1600601 [TBL] [Abstract][Full Text] [Related]
10. [The prevention of the myocardial toxicity of doxorubicin with superoxide dismutase]. Villani F; Galimberti M; Favalli L; Rozza A; Lanza E; Poggi P G Ital Cardiol; 1991 Jun; 21(6):633-41. PubMed ID: 1743445 [TBL] [Abstract][Full Text] [Related]
11. Protective effects of fructose-1,6-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats. Danesi R; Bernardini N; Marchetti A; Bernardini M; Del Tacca M Cancer Chemother Pharmacol; 1990; 25(5):326-32. PubMed ID: 2306792 [TBL] [Abstract][Full Text] [Related]
12. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat. Hirano S; Wakazono K; Agata N; Iguchi H; Tone H Drugs Exp Clin Res; 1994; 20(4):153-60. PubMed ID: 7813387 [TBL] [Abstract][Full Text] [Related]
13. Effect of flunarizine on the delayed cardiotoxicity of doxorubicin in rats. Villani F; Galimberti M; Monti E; Piccinini F; Poggi P; Lanza E; Rozza A; Favalli L Pharmacol Res; 1991 Feb; 23(2):195-202. PubMed ID: 2062794 [TBL] [Abstract][Full Text] [Related]
15. Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat. Jensen RA; Acton EM; Peters JH Cancer Res; 1984 Sep; 44(9):4030-9. PubMed ID: 6744318 [TBL] [Abstract][Full Text] [Related]
16. Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein. Andreadou I; Papaefthimiou M; Zira A; Constantinou M; Sigala F; Skaltsounis AL; Tsantili-Kakoulidou A; Iliodromitis EK; Kremastinos DT; Mikros E NMR Biomed; 2009 Jul; 22(6):585-92. PubMed ID: 19308947 [TBL] [Abstract][Full Text] [Related]
17. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. Jensen RA; Acton EM; Peters JH J Cardiovasc Pharmacol; 1984; 6(1):186-200. PubMed ID: 6199603 [TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity and antitumor activity of a copper(II)-doxorubicin chelate. Monti E; Paracchini L; Piccinini F; Malatesta V; Morazzoni F; Supino R Cancer Chemother Pharmacol; 1990; 25(5):333-6. PubMed ID: 2155062 [TBL] [Abstract][Full Text] [Related]
19. Protective effect of CardiPro against doxorubicin-induced cardiotoxicity in mice. Mohan IK; Kumar KV; Naidu MU; Khan M; Sundaram C Phytomedicine; 2006 Mar; 13(4):222-9. PubMed ID: 16492523 [TBL] [Abstract][Full Text] [Related]
20. Doxorubicin cardiotoxicity: contractile changes after long-term treatment in the rat. Jensen RA J Pharmacol Exp Ther; 1986 Jan; 236(1):197-203. PubMed ID: 3941392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]